title: Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response.
abstract: Wilms tumor relapses are infrequent, occurring in approximately 15% of favorable histology patients. Very few cases of late recurrent relapse exist in the literature. Long-term survival after autologous stem cell rescue ranges from 40% to 73%, but there are very few reports of patients transplanted in their third complete response. We report a late recurrent relapse of Wilms tumor successfully treated with high-dose chemotherapy and autologous stem cell rescue in his third complete response who remains disease free 15 months posttransplant.
authors.affiliation: Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: Evangeline
authors.initials: E
authors.lastname: Brown
authors.forename: Andre
authors.initials: A
authors.lastname: Hebra
authors.forename: Joseph
authors.initials: J
authors.lastname: Jenrette
authors.forename: Michelle
authors.initials: M
authors.lastname: Hudspeth
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D016879:Salvage Therapy / Q000379:methods; D009396:Wilms Tumor / Q000628:therapy*
chemical_list: D005047:Etoposide; D016190:Carboplatin; D008558:Melphalan